Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. HE5 ELR characterization.
  • Fig. S2. Characterization of chemically modified ELRs.
  • Fig. S3. Degradable hydrogel rheological assessment.
  • Fig. S4. Enzymatic cleavage of degradable versus nondegradable ELR by MMP-2.
  • Fig. S5. Enzymatic cleavage of degradable versus nondegradable ELR by MMP-9.
  • Fig. S6. Enzymatic cleavage of degradable versus nondegradable ELR by MMP-13.
  • Fig. S7. Enzymatic cleavage of degradable versus nondegradable ELRs-hydrogel by MMP-2.
  • Fig. S8. Enzymatic cleavage of degradable versus nondegradable ELRs-hydrogel by MMP-9.
  • Fig. S9. Enzymatic cleavage of degradable versus nondegradable ELRs-hydrogel by MMP-13.
  • Fig. S10. Enzymatic cleavage of degradable versus nondegradable ELRs and ELRs-hydrogels by Cat K.
  • Fig. S11. Validation of ovine model of NSTEMI infarct.
  • Fig. S12. EF and FS case profile plots presented for each response over time by treatment.
  • Fig. S13. LVEDD and LVESD case profile plots presented for each response over time by treatment.
  • Fig. S14. Post-ischemic remodeling in PBS-injected and untreated infarcted hearts.
  • Fig. S15. Raman analysis of myocardial infarcted tissue.
  • Fig. S16. Degradable ELRs-hydrogel limited the post-ischemic remodeling damage observed in non-transmural infarcts.
  • Fig. S17. Volcano plots of DEG data from RNA-seq.
  • Fig. S18. Inflammatory and remodeling-related markers at day 28 after MI.
  • Fig. S19. Degradable ELRs-hydrogel allows angiogenesis-related stromal cell invasion and endothelial cell sprouting capacity in vitro.
  • Fig. S20. Glycoprofile analysis after degradable hydrogel treatment.
  • Fig. S21. Terminal α-Gal in O-linked glycans.
  • Fig. S22. Angiogenic response 21 days after multiple ELRs-hydrogel injections in vivo.
  • Fig. S23. IPA analysis highlighted an arrested inhibition of GATA4 in degradable ELRs-hydrogel group.
  • Fig. S24. Nuclear swelling in border zone cardiomyocytes.
  • Fig. S25. Schematics of the ELRs-hydrogel intervention after MI.
  • Fig. S26. Schematics of isotropic uniform random sampling.
  • Table S1. Amino acid composition analysis of the HE5 ELR by high-performance liquid chromatography.
  • Table S2. Storage and loss moduli values of degradable ELRs-hydrogel.
  • Table S3. Analysis of HE5 ELR cleavage by MMP-2, MMP-9, and MMP-13.
  • Table S4. Cell viability assessment of degradable and nondegradable ELRs.
  • Table S5. LVEDD and LVESD at day 7 after MI (time of injection) and end point (28 days after MI).
  • Table S6. List of lectins printed on lectin microarrays, with origin, abbreviation, and carbohydrate specificity.
  • Legends for tables S7 and S8
  • Legends for data files S1 to S3
  • References (68–82)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S7 (Microsoft Excel format). N-linked glycan structures detected in healthy and infarcted myocardial cell membrane samples.
  • Table S8 (Microsoft Excel format). O-linked glycan structures detected in healthy and infarcted myocardial cell membrane samples.
  • Data file S1 (Microsoft Excel format). Raw data for Figs. 1 to 5.
  • Data file S2 (Microsoft Excel format). Raw data for figs. S1 to S22.
  • Data file S3 (Microsoft Excel format). Raw data for proteomic analysis.

More From Science Translational Medicine